Kratzsch J, Knerr I, Galler A, Kapellen T, Raile K, Körner A, Thiery J, Dötsch J, Kiess W
Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Germany.
Eur J Endocrinol. 2006 Oct;155(4):609-14. doi: 10.1530/eje.1.02261.
Type 1 diabetes mellitus (T1DM) leads to increased serum levels of the soluble leptin receptor (sOB-R) by an as yet unknown cellular mechanism. The aim of our study was to investigate potential metabolic factors that may be associated with the induction of the sOB-R release from its membrane receptor.
Twenty-five children (aged between 1.5 and 17.0 years) were studied at the onset of T1DM. Blood samples were collected before (n = 25), during the first 18 h (mean +/- S.D. 11.1 +/- 4.3 h, n = 16) and 92 h (47.5 +/- 22.5 h; n = 14) after beginning insulin therapy. Serum sOB-R and leptin levels were determined by in-house immunoassays.
The sOBR-level and the molar sOB-R/leptin ratio were significantly higher before than after starting insulin treatment (P < 0.05). In contrast, leptin levels were significantly lower (P < 0.05) before insulin therapy. The correlation between sOB-R and blood glucose (r = 0.49; P < 0.05), as well as sOB-R with parameters of ketoacidosis, such as pH (r = -0.72), base excess (r = -0.70), and bicarbonate (r = -0.69) (P < 0.0001) at diagnosis of T1DM remained significant during the first 18 h of insulin treatment. Multiple regression analysis revealed that base excess predicted 41.0% (P < 0.001), age 16.4% (P < 0.05), and height SDS 13.9% (P < 0.01) of the sOB-R variance.
Metabolic decompensation in children with new onset T1DM is associated with dramatic changes of the leptin axis; serum levels of sOB-R are elevated and of leptin are reduced. The molar excess of sOB-R over leptin (median 11.3) in this condition may contribute to leptin insensitivity. Upregulation of the soluble leptin receptor appears to be a basic mechanism to compensate for intracellular substrate deficiency and energy-deprivation state.
1型糖尿病(T1DM)通过一种尚不清楚的细胞机制导致血清可溶性瘦素受体(sOB-R)水平升高。我们研究的目的是调查可能与sOB-R从其膜受体释放诱导相关的潜在代谢因素。
对25名儿童(年龄在1.5至17.0岁之间)在T1DM发病时进行研究。在开始胰岛素治疗前(n = 25)、治疗后的前18小时(平均±标准差11.1±4.3小时,n = 16)和92小时(47.5±22.5小时;n = 14)采集血样。血清sOB-R和瘦素水平通过内部免疫测定法测定。
开始胰岛素治疗前的sOBR水平和sOB-R/瘦素摩尔比显著高于治疗后(P < 0.05)。相反,胰岛素治疗前瘦素水平显著较低(P < 0.05)。在T1DM诊断时,sOB-R与血糖之间的相关性(r = 0.49;P < 0.05),以及sOB-R与酮症酸中毒参数如pH(r = -0.72)、碱剩余(r = -0.70)和碳酸氢盐(r = -0.69)之间的相关性(P < 0.0001)在胰岛素治疗的前18小时内仍然显著。多元回归分析显示,碱剩余预测了sOB-R变异的41.0%(P < 0.001),年龄预测了16.4%(P < 0.05),身高标准差预测了13.9%(P < 0.01)。
新诊断的T1DM儿童的代谢失代偿与瘦素轴的显著变化有关;血清sOB-R水平升高而瘦素水平降低。在这种情况下,sOB-R相对于瘦素的摩尔过量(中位数11.3)可能导致瘦素不敏感。可溶性瘦素受体的上调似乎是补偿细胞内底物缺乏和能量剥夺状态的一种基本机制。